When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...

Tsukuba, Japan—Follicular lymphoma is a common and recurrent form of malignant lymphoma. Although the role of T cells (a type of lymphocyte) in its development has been suggested, the diversity and ...

For some people, treating follicular lymphoma involves active surveillance until severe symptoms develop. For others, chemoimmunotherapy, radiation therapy, or targeted treatments may be necessary.

The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...

Sponsored advertising content is provided by Genmab A/S and AbbVie and does not necessarily reflect the views of CURE Each person’s experience with follicular lymphoma (FL) is unique. Whether you’re ...

Explore the advancements in bispecific antibodies for follicular lymphoma, addressing treatment options, toxicities, and unmet patient needs in cancer care. Bispecific antibodies were developed to ...

At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) ...

What Is Epkinly, and Why Does It Matter? Epkinly (epcoritamab-bysp) is a type of cancer treatment called a bispecific antibody that helps your immune system find and destroy certain cancer cells by ...

In the TRANSCEND FL trial, 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response* Breyanzi demonstrated sustained clinical benefit, with 75.7% of patients still ...

Andrew Zelenetz, MD, PhD, discusses the dual strategy of using the duration of benefit metric and re-biopsy to navigate complex sequencing decisions in targeted lymphoma therapy. A central challenge ...